Amgen Taiwan’s General Manager Daniel Villegas began his career in the fast-moving consumer goods space before transitioning into biopharmaceuticals. His professional journey has spanned four continents and covered various therapeutic areas, from rare diseases to immunology. A California native, Villegas earned his BA from San Diego State University and MBA from Michigan State University. In…
BoonHuey Ee, general manager of Merck Healthcare Taiwan, Hong Kong, and Macau, is a Merck veteran with more than two decades’ experience in the healthcare industry. Ee has acquired in-depth knowledge of local and regional markets and had extensive exposure to various complex healthcare environments from her various managerial roles across the Asia-Pacific region. As…
Research-based biopharmaceutical multinational AstraZeneca, one of the earliest healthcare companies to enter the Taiwan market, has been working to deliver the best in patient care in Taiwan for over 70 years. The company’s dedication to advancing medical science is reflected in its innovation and outstanding performance in R&D. It is also focused on “beyond the…
2020 has been an extraordinarily challenging year for people, governments, and companies around the world. For biopharma multinational Amgen, which this year turns 40, and its Taiwan affiliate, now in its fifth year of operation on the island, 2020 has become a time for reflection. As different countries experience varying levels of disruption and negative…
Pfizer has called on the biopharmaceutical industry to join the company in committing to unprecedented collaboration to combat COVID-19. “In this troubling time, Pfizer is committed to doing all we can to respond to the COVID-19 pandemic,” Dr. Albert Bourla, the company’s Chairman and CEO, said in a statement. “Many companies, including Pfizer, are working…
Positioning Taiwan as an Asia-Pacific Biomedical R&D Hub – Is Taiwan Ready for the Top Spot?” That provocative topic was the theme of a half-day conference – held April 25 at the Chang Yung-Fa Foundation’s International Convention Center – that featured a number of prominent expert speakers and panelists from both Taiwan and internationally. The…
This is Part 3 of the cover story on Pharmaceuticals: Links to Part 1, Part 2 The controversy over the biotech company has ensnared the president of Academia Sinica, as well as the company chairman. The Taiwanese biotech firm OBI Pharma has struggled since revealing in late February that Phase III clinical trials for its…
